{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:51:15Z","timestamp":1762505475750},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.jacl.2009.04.052","type":"journal-article","created":{"date-parts":[[2009,5,5]],"date-time":"2009-05-05T05:30:04Z","timestamp":1241501404000},"page":"167-178","source":"Crossref","is-referenced-by-count":18,"title":["The SLIM study: Slo-Niacin\u00ae and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia"],"prefix":"10.1016","volume":"3","author":[{"given":"Robert H.","family":"Knopp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara M.","family":"Retzlaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Fish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Dowdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Twaddell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thuy","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pathmaja","family":"Paramsothy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl","key":"10.1016\/j.jacl.2009.04.052_bib1","doi-asserted-by":"crossref","first-page":"48B","DOI":"10.1016\/j.amjcard.2008.02.038","article-title":"Comprehensive lipid management vs. aggressive LDL lowering to reduce cardiovascular risk","volume":"101","author":"Knopp","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2009.04.052_bib2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"Jama"},{"key":"10.1016\/j.jacl.2009.04.052_bib3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2009.04.052_bib4","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2009.04.052_bib5","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2009.04.052_bib6","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2009.04.052_bib7","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","article-title":"The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3","volume":"22","author":"Taylor","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2009.04.052_bib8","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMcp070061","article-title":"Clinical practice","volume":"357","author":"Brunzell","year":"2007","journal-title":"Hypertriglyceridemia. N Engl J Med"},{"key":"10.1016\/j.jacl.2009.04.052_bib9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJM199908123410707","article-title":"Drug treatment of lipid disorders","volume":"341","author":"Knopp","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2009.04.052_bib10","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI107332","article-title":"Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia","volume":"52","author":"Goldstein","year":"1973","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2009.04.052_bib11","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1161\/01.CIR.85.6.2025","article-title":"Familial lipoprotein disorders in patients with premature coronary artery disease","volume":"85","author":"Genest","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2009.04.052_bib12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0026-0495(85)90092-7","article-title":"Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin","volume":"34","author":"Knopp","year":"1985","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2009.04.052_bib13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jacl.2007.07.008","article-title":"Revisiting niacin: reviewing the evidence","volume":"1","author":"Vaccari","year":"2007","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2009.04.052_bib14","doi-asserted-by":"crossref","first-page":"14B","DOI":"10.1016\/j.amjcard.2008.02.028","article-title":"Niacin use and cutaneous flushing: mechanisms and strategies for prevention","volume":"101","author":"Davidson","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2009.04.052_bib15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MOL.0b013e3282364add","article-title":"Niacin in cardiovascular prevention: mechanisms, efficacy, and safety","volume":"18","author":"Guyton","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2009.04.052_bib16","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.amjcard.2008.02.092","article-title":"Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)","volume":"101","author":"Ballantyne","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2009.04.052_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00129784-200808020-00001","article-title":"Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study","volume":"8","author":"Karas","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacl.2009.04.052_bib18","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2006.11.037","article-title":"Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)","volume":"192","author":"McKenney","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2009.04.052_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0002-9149(97)00303-2","article-title":"Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg\/dl in patients with hyperlipidemia and coronary artery disease","volume":"80","author":"Brown","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2009.04.052_bib20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0002-9149(92)90868-Y","article-title":"Marked benefit with sustained-release niacin therapy in patients with \u201cisolated\u201d very low levels of high-density lipoprotein cholesterol and coronary artery disease","volume":"69","author":"Lavie","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2009.04.052_bib21","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0025-6196(12)60824-6","article-title":"Low-dose, time-release nicotinic acid: effects in selected patients with low concentrations of high-density lipoprotein cholesterol","volume":"67","author":"Squires","year":"1992","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacl.2009.04.052_bib22","series-title":"Methods in enzymology, part B: characterization, cell biology, and metabolism","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0076-6879(86)29064-3","article-title":"Enzymatic methods for quantification of lipoprotein lipids","author":"Warnick","year":"1986"},{"key":"10.1016\/j.jacl.2009.04.052_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0009-8981(93)90062-9","article-title":"Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels","volume":"223","author":"Nakajima","year":"1993","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jacl.2009.04.052_bib24","series-title":"Physicians' desk reference","year":"2006"},{"key":"10.1016\/j.jacl.2009.04.052_bib25","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2009.04.052_bib26","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-0495(98)90284-0","article-title":"Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia","volume":"47","author":"Knopp","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2009.04.052_bib27","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2009.04.052_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jacl.2008.12.003","article-title":"Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD","volume":"3","author":"Jafri","year":"2009","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2009.04.052_bib29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/01.ATV.0000053385.64132.2D","article-title":"Smallest LDL particles are most strongly related to coronary disease progression in men","volume":"23","author":"Williams","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2009.04.052_bib30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/01.ATV.0000154144.73236.f4","article-title":"Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study","volume":"25","author":"St-Pierre","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2009.04.052_bib31","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1161\/01.CIR.99.15.1959","article-title":"Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density","volume":"99","author":"Zambon","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2009.04.052_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jacl.2007.05.003","article-title":"Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: A Subgroup Analysis of the HDL-Atherosclerosis Treatment Study (HATS)","volume":"1","author":"Vittone","year":"2007","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2009.04.052_bib33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0026-0495(03)00030-1","article-title":"Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content","volume":"52","author":"Poynten","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2009.04.052_bib34","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jacl.2007.10.002","article-title":"Efficacy of controlled-release niacin in treatment of metabolic syndrome: correlation to surrogate markers of atherosclerosis, vascular reactivity and inflammation","volume":"1","author":"Vaccari","year":"2007","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2009.04.052_bib35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM199502233320801","article-title":"Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease","volume":"332","author":"Treasure","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2009.04.052_bib36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2337\/db08-1228","article-title":"Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance","volume":"58","author":"Haus","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.jacl.2009.04.052_bib37","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.2337\/db07-1062","article-title":"Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle","volume":"57","author":"Nieto-Vazquez","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.jacl.2009.04.052_bib38","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jama.1994.03510330050033","article-title":"A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients","volume":"271","author":"McKenney","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2009.04.052_bib39","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/archinte.1991.00400070172024","article-title":"Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia","volume":"151","author":"Keenan","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2009.04.052_bib40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jacl.2009.02.003","article-title":"Flushing and other dermatologic adverse events associated with extended-release niacin therapy","volume":"3","author":"Guyton","year":"2009","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2009.04.052_bib41","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1056\/NEJMp0900665","article-title":"Health care and the American Recovery and Reinvestment Act","volume":"360","author":"Steinbrook","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2009.04.052_bib42","doi-asserted-by":"crossref","first-page":"58B","DOI":"10.1016\/j.amjcard.2008.02.039","article-title":"Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk","volume":"101","author":"Brown","year":"2008","journal-title":"Am J Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287409001998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287409001998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T17:32:24Z","timestamp":1558287144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287409001998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S1933287409001998"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2009.04.052","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}